title: Trastuzumab emtansine and cost-based decision making.
authors.lastname: The Lancet
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D003362:Cost-Benefit Analysis; D017277:Drug Approval / Q000191:economics*; D016527:Drug Costs; D006801:Humans; D007356:Insurance, Pharmaceutical Services; D013222:State Medicine; D000068878:Trastuzumab / Q000191:economics / Q000627:therapeutic use*; D006113:United Kingdom
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab